CONMED Corporation (CNMD) Guidance & Earnings Results

On 2026-07-29 CONMED Corporation raised guidance: "FY26 adjusted diluted EPS raised to $4.48-$4.60 from $4.30-$4.45; FY26 net sales guidance narrowed to $1,358-$1,373M from $1,350-$1,375M; organic constant currency growth 5.0-6.0% vs prior…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CNMDCONMED CorporationFollow CNMD — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 1.5B
P/E TTM: 26.6
Dividend yield: 1.2%
52-week: —
Next earnings: 28 Oct, in 4 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
29 Jul 26	Raised	FY26 adjusted diluted EPS raised to $4.48-$4.60 from $4.30-$4.45; FY26 net sales guidance narrowed to $1,358-$1,373M from $1,350-$1,375M; organic constant currency growth 5.0-6.0% vs prior 5.0-6.5% · full year
29 Apr 26	Raised	Organic constant currency revenue growth guidance raised from 4.5-6.0% to 5.0-6.5%; reported revenue guidance narrowed to $1.350-1.375B · full year
28 Jan 26	Reaffirmed	FY2026 revenue $1.345-1.375B, adjusted EPS $4.30-4.45 · full year
5 Nov 25	Raised	FY2025 revenue $1.365-1.372B (prior $1.356-1.378B); adjusted EPS $4.48-4.53 (prior $4.40-4.55) · full year
30 Jul 25	Raised	FY2025 revenue raised to $1.356-1.378B from $1.350-1.378B; FY2025 adjusted diluted EPS raised to $4.40-4.55 from $4.31-4.46; tariff headwind ~$0.09 EPS in H2 2025 · full year

CONMED Corporation — questions

What guidance did CONMED Corporation give?: On 2026-07-29: "FY26 adjusted diluted EPS raised to $4.48-$4.60 from $4.30-$4.45; FY26 net sales guidance narrowed to $1,358-$1,373M from $1,350-$1,375M; organic constant currency growth 5.0-6.0% vs prior 5.0-6.5%"
When does CONMED Corporation report earnings?: CONMED Corporation's next earnings report is expected on 2026-10-28.

Every figure on this page comes from CONMED Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.